Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIA-2291 in ACS
NCT00552188Phase 2Completed
- Sponsor
- Tallikut Pharmaceuticals, Inc.
- Start
- Oct 2007
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Atreleuton in acute coronary syndrome (ACS), sponsored by Tallikut Pharmaceuticals, Inc.. Started Oct 2007; status: completed.
02
Drugs
Atreleuton
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00552188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00552188.